INmune Bio closed at $1.18 on Nov 5, down 11.65%, 53.2% below its 52-week closing high. Volume of 486.5K shares was 1.83× its 20-day average (above normal).
Split-adjusted performance: -36.8% over one month, -17.8% over six months, -31.7% over one year.
Short interest was 2.9M shares at the Oct 15 settlement, up 8.6% from the prior report (11.7% of float, 8.2 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INMBINmune Bio | $1.18 | −11.65% | −17.8% | — | — | — | $36.4M | |
| PTHSPelthos Therapeutics | $9.30 | −8.37% | −62.8% | — | −150.1% | — | $36.6M | Compare |
| EXOZeXoZymes | $4.11 | −4.64% | −58.9% | — | — | — | $38.2M | Compare |
| ELUTElutia | $0.7509 | −1.15% | −24.8% | −11.6% | −315.0% | 0.6 | $33.3M | Compare |
| LONALeonaBio | $4.34 | −4.93% | −56.0% | — | — | — | $40.9M | Compare |
| CRBUCaribou Biosciences | $0.4123 | −7.22% | −78.1% | −43.8% | −1619.9% | — | $44.2M | Compare |
| ALGSAligos Therapeutics | $4.51 | −10.16% | −25.2% | +2778.5% | −5.4% | — | $28.2M | Compare |
| IMAImageneBio | $4.17 | +1.59% | −29.5% | — | — | — | $47.3M | Compare |
| TILInstil Bio | $6.99 | 0.00% | −13.0% | — | — | — | $47.4M | Compare |
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
